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ORIGINAL ARTICLEDynamic Contrast-Enhanced Magnetic Resonance Imaging
Suggests Normal Perfusion in Normal-Appearing White
Matter in Multiple Sclerosis
Michael Ingrisch, PhD,* Steven Sourbron, PhD,† Sina Herberich, MD,‡
Moritz Jörg Schneider, Dipl-Phys, MSc,* Tania Kümpfel, MD,§ Reinhard Hohlfeld, MD,§||
Maximilian F. Reiser, MD,‡ and Birgit Ertl-Wagner, MD‡Objectives: Multiple sclerosis (MS) is a chronic, inflammatory disease of the
central nervous system and has been associated with reduced perfusion in
normal-appearing white matter (NAWM). The magnitude of this hypoperfusion
is unclear. The present study aims to quantify NAWM perfusion with dynamic
contrast-enhanced (DCE) magnetic resonance imaging (MRI) in patients with
relapsing-remitting (RR) MS and in a control group.
Materials and Methods: The statistical power of a DCE-MRI acquisition to
reveal hypoperfusion in MS was estimated using a Monte Carlo simulation:
synthetic tissue curves with a contrast-to-noise ratio of 8 were generated for
MS patients and control group using perfusion values reported in previous
studies. A compartment-uptake model was fitted to these curves, yielding es-
timates of cerebral blood flow (CBF), cerebral blood volume (CBV), and
permeability-surface area product (PS). This was repeated 1000 times. Mean
and standard deviation of the resulting distributions were used to calculate the
statistical power of a DCE-MRI study to detect perfusion differences between
16 control subjects and 24 MS subjects.
In an institutional review board–approved study, patients with RR-MS (n = 24;
mean age, 36 years; 17 women, mean Enhanced Disability Status Scale score,
3.25) and patients without history or symptoms of neurological disorder
(n = 16; mean age, 49 years; 9 women) underwent a DCE-MRI examination with
a previously established MRI protocol (3D SPGR sequence; 2.1 seconds tempo-
ral resolution; 44 slices; spatial resolution, 1.7 1.7 3 mm). Regions were de-
fined manually in the middle cerebral artery; in the frontal, periventricular, and
occipital NAWM; in the pons; and in the thalamus, and CBF, CBV, and PS were
quantified using a compartment-uptake model.
Parameter differences between MS and control groups were evaluated using a
mixed linear model with subjects as random effect and controlling for age and
sex. A P value of less than 0.05was considered to indicate statistical significance.
Results: For all but one of previously reported effect sizes, the simulation study es-
timated a statistical power of 80% to 100% to detect reduced CBF inMS. In the pa-
tient study, mean (standard deviation) CBF in NAWM was 11.0 (15.1) and 10.4
(8.2) mL/100 mL per minute in the MS and control groups, respectively. Mean
CBV in NAWM was 0.50 (0.45) mL/100 mL in the MS group and 0.48 (0.28)
mL/100 mL in the control group. Mean values of PS in NAWM were 0.002 mLReceived for publication June 13, 2016; and accepted for publication, after revision,
July 8, 2016.
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Copyright © 2017 Wolters Kluwer H(0.027)/100 mL per minute in the control group and −0.001 (0.015) mL/100 mL
per minute in the MS patients. Differences between patient groups were not statis-
tically significant for CBF, CBV, mean transit time, and PS (P = 0.44, P = 0.20,
P = 0.78,P= 0.66, respectively). In both groups, the influence of age on any param-
eter was nonsignificant. Cerebral blood flow and CBV in the thalamus and pons
were significantly higher than in NAWM regions (P < 1e-4); mean transit time
was significantly shorter than in NAWM (P < 1e-4). Permeability-surface area
product was not significantly different from zero (P > 0.25) in all evaluated regions.
Conclusions: Despite high statistical power, we could not confirm previous re-
ports of NAWM hypoperfusion in MS. This indicates that, at least in our patient
cohort, potential hypoperfusion is much less pronounced than reported in
previous studies.
Key Words: dynamic contrast-enhanced MRI, multiple sclerosis,
normal-appearing white matter
(Invest Radiol 2017;52: 135–141)
M ultiple sclerosis (MS) is a chronic, inflammatory autoimmunedisease of the central nervous system. The disease often follows
a relapsing-remitting (RR) course, with focal inflammatory demyelinat-
ing lesions being one of the hallmarks of the disorder. In addition, MS
has also been reported to be associated with a diffuse reduction of per-
fusion, that is, the blood supply of tissue, in normal-appearing white
matter (NAWM). Early studies using single photon emission computed
tomography or positron emission tomography1–3 reported a significant
reduction of cerebral blood flow (CBF) in the NAWM of patients with
MS as comparedwith healthy control groups. Others have used a contrast
agent-based magnetic resonance imaging (MRI) technique (dynamic
susceptibility-contrast [DSC] MRI) and demonstrated a pronounced re-
duction of cerebral perfusion in patients with MS, as compared with
healthy controls,4–7 with differences of up to 100%. These findings have
led to speculations as to whether this hypoperfusion is a cause or a con-
sequence of MS,8 and potential therapy pathways have also been sug-
gested,9 highlighting the importance of cerebral hypoperfusion in MS
as a potential therapeutic target.10 The magnitude of this hypoperfusion,
however, is unclear. A perfusion difference of only 20%was reported in a
study using arterial spin labeling9 (ASL), whereas another study11 even
identified a subgroup of patients with “highly inflammatory”MS where
NAWM perfusion was not reduced but increased.
In the present work, we aimed to investigate NAWM perfusion
with dynamic contrast-enhanced (DCE) MRI, based on a time-
resolved T1-weighted measurement of the signal enhancement during
and after the administration of contrast agent. Dynamic contrast-
enhanced-MRI is a well-established technique for the measurement
and quantification of extracerebral tissue perfusion and has also been
used for the measurement of hemodynamics in inflammatory lesions
and in NAWM in patients with MS.12 Initially, we performed a simula-
tion study to estimate the statistical power of DCE-MRI to detect cere-
bral hypoperfusion. Subsequently, we conducted a patient study in
which we compared NAWM perfusion in a group of patients with
RR-MS to a group of patients without an inflammatory or demyelinat-
ing disorder of the brain.www.investigativeradiology.com 135
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Simulations and Power Analysis
To assess the effect size and the statistical power of a DCE-MRI
study, a Monte Carlo simulation was performed as follows: values for
CBF and cerebral blood volume (CBV) were drawn from normal distri-



















1 MS M 23 2 1 4.5 0
4 MS F 51 11 6 4 0
5 MS F 31 5 126 5 0
6 MS F 43 13 0 6 3
7 MS F 38 5 36 2 0
8 MS M 31 12 96 2 0
10 MS M 31 0.3 1 1 0
11 MS F 30 0.3 2 1.5 5
13 MS M 30 14 5 3 3
16 MS M 47 7 1 4 0
17 MS M 56 11 7 6 0
19 MS F 34 12 137 3 0
20 MS F 46 21 0 6.5 0
22 MS F 23 3 11 0 1
25 MS F 48 4 5 2.5 0
26 MS F 28 10 1 4 1
29 MS F 55 11 9 4 1
30 MS F 30 0.5 5 2 0
31 MS F 42 12 0 4 0
32 MS M 21 0.8 32 0 2
33 MS F 28 2 8 2 0
37 MS F 33 0.5 1 4 0
40 MS F 40 4 8 3 2
44 MS F 24 6 1 4 0
2 Control F 20
3 Control F 52
9 Control M 52
15 Control M 67
18 Control F 30
21 Control F 65
23 Control M 38
24 Control F 58
27 Control M 48
28 Control F 32
34 Control M 69
36 Control F 57
39 Control F 63
45 Control M 26
46 Control F 45
48 Control M 66
Age and duration of disease are provided in years, time since last relapse inmonths.
EDSS indicates Enhanced Disability Status Scale; MS, multiple sclerosis;
M, male; F, female.
FIGURE 1. Representative example of defined tissue regions in the frontal
(1 and 2), occipital (3 and 4), and periventricular (5 and 6) NAWM; in
the pons (7); and in the thalamus (8 and 9). Whenever possible, regions
were defined on 3 adjacent slices to increase region size. Figure 1 can be
viewed online in color at www.investigativeradiology.com.
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Copyright © 2017 Wolters Kluwer Hstudies1,4,5,9; Permeability-surface area product (PS) was assumed to
be zero. Using these draws, synthetic tissue signal curves for NAWM
in MS and control patients were generated using an arterial input func-
tion (AIF) from a pilot study12 with a compartment-uptake model. To
these curves, Gaussian noise was added to achieve a contrast-to-noise
ratio (CNR) similar to the pilot study12 (CNR = 8). To the resulting
curve, a compartment-uptake model13 was fitted, yielding estimates
of CBF, CBV, mean transit time (MTT), and PS. This process was re-
peated for 1000 draws to estimate the parameter distributions. Mean
and standard deviation of the resulting distributions were used to cal-
culate effect sizes, estimated as Cohen d,14 and the statistical power of
a DCE-MRI study to detect perfusion differences with 16 subjects in
the control group and 24 subjects in the MS group.
Patients and Imaging
The institutional review board approved this study, and informed
consent was obtained from all participants; methods were carried out in ac-
cordance with the approved guidelines. Twenty-four consecutive patients
with confirmed RR-MS (n = 24; mean age, 36 years; range, 21–56; 17
women; mean Enhanced Disability Status Scale score, 3.25) with a
clinical indication for a contrast-enhanced MRI examination were in-
cluded in the study. Exclusion criteria were relapse at the time point
of imaging or glucocorticoid therapy in the 4 weeks before imaging.
As a control group, patients without history or symptoms of neurolog-
ical disorder (n = 16; mean age, 49 years; range, 20–69; 9 women) were
included; the patients in this control cohort presented for the imaging
evaluation of a hearing disorder to rule out vestibular schwannoma.© 2016 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
FIGURE 2. Normal distributions of CBF in MS and in control patients, as reported in Adhya et al5 (top left) and in D'haeseleer et al9 (top right). The
corresponding effect sizes are d = 4.92 (top left) and d = 0.51 (top right). After a simulated DCE-MRI measurement, distributions appear broader and
show more overlap (bottom row), resulting in reduced effect sizes of d = 1.3 (bottom left) and d = 0.09 (bottom right), respectively. Figure 2 can be
viewed online in color at www.investigativeradiology.com.
Investigative Radiology • Volume 52, Number 3, March 2017 DCE-MRI Suggests Normal Perfusion in NAWM in MSExclusion criteria for both cohorts were a history of other neurological
disorders other than MS in the MS cohort and hearing loss in the control
cohort, the presence of an intracranial tumor, as well as usual contraindi-
cations for MRI, including cardiac pacemakers, other ferromagnetic im-
plants, claustrophobia, and pregnancy. Detailed patient characteristics are
shown in Table 1.
All measurements were performed on a clinical 3 T scanner
(Magnetom Verio; Siemens Healthcare, Erlangen, Germany). The im-
aging protocol included precontrast 3D T1-weighted sequences, 3DTABLE 2. Overview of Sample Sizes, Reported CBF Values (Mean and Sta
Effect Sizes, and Estimated Statistical Power After a DCE Measurement W
Method nMS ncontrol
CBF MS, mL/100 mL
per minute
CBF C
Brooks et al,1 1985 PET 15 13 21 (4)
Sun et al,2 1998 PET 20 14 17.7 (5.0)
Law et al,4 2004 DSC 17 17 16.3 (9.5)
Adhya et al,5 2006 DSC 11 11 34.6 (1.8)
D'haeseleer et al,9
2013
ASL 15 15 40.0 (17.3)
In the study by D'haeseleer et al, no CBV values were reported, so that the simulat
CBF indicates cerebral blood flow; DCE, dynamic contrast-enhanced; MS, multip
susceptibility-contrast; ASL, arterial spin labeling.
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer HFLAIR sequences, and axial T2-weighted sequences as well as
contrast-enhanced 3D T1-weighted sequences. One hundred seventy
DCE-MRI volumes were acquired during a total acquisition time of
6 minutes with a T1-weighted 3D spoiled gradient echo sequence with
a coverage of the full brain at a spatial resolution of 1.7 1.7 3 mm3
and a temporal resolution of 2.1 seconds per volume, as described pre-
viously12 (TE/TR, 0.85/2.29 milliseconds; flip angle, 19 degrees; band-
width, 1220 Hz/pixel; field of view, 220 178 132 mm; matrix size,
128  104  44; parallel imaging with acceleration factor 2; TWISTndard Deviation in Both Groups), Reported Effect Sizes, Simulated









27 (5) 1.39 1.23 0.92
23.9 (5.6) 1.22 1.03 0.81
34.8 (8.4) 2.14 2.02 1.00
42.8 (1.7) 4.92 1.65 0.99
48.0 (14.9) 0.51 0.03 0.05
ion was performed with an assumed CBV value 2%.
le sclerosis; PET, positron emission tomography; DSC, dynamic
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FIGURE 3. Top: Exemplary signal enhancement curves from a patient
withMS (subject 44) in gray andwhitematter curves, alongwithmodel
fits. The white matter curve was measured in a region in the occipital
white matter, with CBF = 12.7 mL/100mL per minute, CBV = 0.64mL/
100 mL, and PS = 0.001 mL/100 mL per minute. The gray matter curve
wasmeasured in the left thalamus, themodel fit yielded CBF = 74.2mL/
100 mL per minute, CBV = 2.7 mL/100 mL, MTT = 1.4 s, and
PS = −0.02 mL/100 mL per minute. Bottom: the corresponding AIF.
Both plots display the absolute signal enhancement. Figure 3 can be
viewed online in color at www.investigativeradiology.com.
Ingrisch et al Investigative Radiology • Volume 52, Number 3, March 2017view sharing15 with pA/pB = 0.25/0.22). Ten seconds after the DCE ac-
quisition was started, a standard dose of contrast agent (0.1 mmol/kg
body weight of gadobutrol, Bayer Schering) was injected intravenously
at a rate of 3 mL/s. The injection was split into 2 injections separated by
60 seconds to reduce the peak concentration during the first pass of the
contrast agent; each injection was followed by a flush of 30 mL saline
solution with the same injection rate.
Image Analysis and Quantification
Structural MRI sequences of both cohorts were reviewed by a
neuroradiologist (B.E.W.) with more than 15 years of experience in
neuroimaging to rule out vestibular or cochlear schwannomas, other in-
tracranial tumors, cerebral hemorrhage, cerebral microbleeds, hydro-
cephalus, acute or subacute cerebral ischemia, and other diseases that
may affect cerebral perfusion.
Image postprocessing was done using in-house written soft-
ware16 as described previously.12 To aid the definition of evaluation
regions, maps of the average baseline signal S0 before the arrival of
contrast agent and of the area under the curve (AUC) of the signal
enhancement S(t) − S0 were calculated.
The AIF was measured in the middle cerebral artery. A rectangu-
lar region encompassing themiddle cerebral artery was definedmanually
on the AUC maps; the 6 voxels with the highest AUC values within this
region were used to measure the signal enhancement course in the artery.
To correct for partial volume effects, a venous output curvewasmeasured
in the single pixel with the highest AUC value in the sagittal sinus (SS).
For the assessment of perfusion, tissue regions were defined bi-
laterally in the frontal, periventricular, and occipital white matter; in the
thalami; and in the pons (see Fig. 1). For the definition of these regions,
the map of the baseline signal was used. In the MS cohort, FLAIR im-
ages were visually coregistered to the baseline map to ensure that no
FLAIR-hyperintense areas were included in the NAWM regions.
Whenever possible, regions were defined on consecutive slices to in-
crease region size.
Averaged time-intensity curveswere calculated for all previously
defined regions and converted to contrast agent concentration using the
absolute signal enhancement S(t) − S0. The absolute signal enhance-
ment is proportional to the contrast agent concentration and, unlike
the relative signal enhancement, does not depend on the precontrast
relaxation time.13 The AIF was corrected for partial volume effects
using the reference measurement in the SS.12 Briefly, the apparent
blood volume in the SS was determined by deconvolving the venous
curve with the measured AIF, which is affected by partial volume ef-
fects. These partial volume effects cause an overestimation of the appar-
ent venous blood volume. Because the true blood volume in the sinus
sagittalis voxel can be assumed to be 100%, a correction factor for
the AIF can be calculated.17 This correction factor was then used to re-
scale the AIF. The arterial plasma concentration was derived by scaling
the arterial blood concentration with 1/1(1 – hct), where hct is the he-
matocrit value. A constant hematocrit of hct = 0.45 was assumed be-
cause no individual hematocrit values were available.
A compartment uptake model13 was then fitted to the signal en-
hancement curves in each region, yielding estimates of CBF, CBV,
MTT, and PS.
Statistical Analysis
Statistical evaluation of the data was performed in R18 using the
packages lme4 and lmerTest.19,20 Differences in CBF, CBV, and PS be-
tween MS patients and the control group were evaluated using a linear
mixed model with subjects as random effect. Each perfusion parameter
was modeled separately. The influence of duration of disease, number
of contrast-enhancing lesions, and time since last relapse were included
into the model and tested for statistical relevance. Fixed effects of the
final model were group, age, sex, and region (frontal, occipital, and138 www.investigativeradiology.com
Copyright © 2017 Wolters Kluwer Hperiventricular NAWM; thalamus; pons). A P value of less than 0.05
was considered to indicate statistical significance.
In an additional analysis, patients with contrast-enhancing le-
sions were excluded and the evaluation was repeated.
RESULTS
Simulations and Power Analysis
The simulated DCE-MRI acquisition resulted in a broadening
compared with the original parameter distributions based on the reported
parameter values, due to the low CNR that is typical for DCE-MRI in the
presence of an intact blood-brain barrier (BBB).12,17 Original and simu-
lated CBF distributions for 2 selected studies are shown in Figure 2.
Based on the resulting effect sizes, a DCE-MRI study with 16 patients
in the control group and 24 patients in the MS group has a statistical
power of 99% to discriminate CBF between the 2 patient groups for
CBF differences as reported in a DSC study.5 For the CBF differences
from a recent ASL study,9 displayed top right in Figure 2, the statistical
power reduces to 6% for the same sample sizes. Reported and simulated
effect sizes from several earlier studies, along with the estimated statisti-
cal power of a DCE-MRI study, are displayed in Table 2. For most© 2016 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
FIGURE 4. Overview of determined values of CBF (A) given in mL/100 mL per minute, CBV (B) given in mL/100 mL, MTT (C) in seconds, and PS (D) in
mL/100mL per minute in patients and control group in all evaluated regions. The centerline of the boxes indicates the median; the boxes indicate the
range from the 25th to 75th percentile; the whiskers extend to the highest value within 1.5* interquartile range; values outside the whiskers are plotted
as dots.
Investigative Radiology • Volume 52, Number 3, March 2017 DCE-MRI Suggests Normal Perfusion in NAWM in MSpreviously reported effect sizes, the estimated statistical power of a DCE-
MRI study is larger than 80%.
Quantification
Representative tissue curves for gray matter and NAWM, mea-
sured in a patient withMS (subject 44), are shown in Figure 3. The char-
acteristic dual-peak form of both curves results from the double
injection of contrast agent. The amplitude of the NAWM curve is much
smaller, reflecting the lower values of CBF and CBV.
Quantitative parameter estimates of CBF, CBV, and PS are sum-
marized in Figure 4. Cerebral blood flow and CBV were increased in
the pons and thalamus, as compared with NAWM, and are similar in
MS patients and control group (see Fig. 4). Likewise, the PS does not
demonstrate obvious differences between groups. The mean CBF in
NAWM was 11.0 (15.1) and 10.4 (8.2) mL/100 mL per minute in the
MS and control groups, respectively. The mean CBV in NAWM was
0.50 (0.45) mL/100 mL in the MS group and 0.48 (0.28) mL/100 mL
in the control group. The mean values of PS in NAWM were
0.002 mL (0.027) mL/100 mL per minute in the control group and
−0.001 (0.015) mL/100 mL per minute in the MS patients.
Differences between patient groups were not statistically signifi-
cant for CBF, CBV, MTT, and PS (P = 0.44, P = 0.20, P = 0.78,
P = 0.66, respectively). Sex had no significant influence on either of
these parameters; in both groups, the influence of age on any parameter
was nonsignificant. Cerebral blood flow and CBV in the thalamus and
pons were significantly higher than in NAWM regions (P < 1e-4); MTT
was significantly shorter than in NAWM (P < 1e-4). Permeability-
surface area product was not significantly different from zero
(P > 0.25) in all evaluated regions.Medication, total duration of disease,© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer Hnumber of contrast-enhancing lesions, and time since last relapse had
no significant influence and were therefore not included in the final sta-
tistical model. Excluding the 8 patients with active, contrast-enhancing
lesions from the statistical analysis did not alter the qualitative outcome
of the statistical analysis; in particular, no significant differences be-
tween patient groups could be observed.DISCUSSION
In this study, perfusion parameters in NAWM in patients with
RR-MSwere compared with a control group to assess whether previous
findings of reduced NAWM perfusion in RR-MS could be confirmed
by means of DCE-MRI. The simulation study demonstrated that our
DCE-MRI study has sufficient statistical power to discriminate previ-
ously reported large CBF differences, whereas small CBF differences,
as reported in a recent study, may be missed due to low statistical power.
In our patient study, we were not able to detect statistically significant
differences between patients with RR-MS and a control group regard-
ing CBF, CBV, and PS in NAWM and in gray matter.
These results are not in line with previous reports that studied
NAWMperfusion in MS. Early nuclear medicine studies1–3 have found
a significantly reduced CBF in patients with MS. These observations
were confirmed by several publications,4–7 who, albeit with partially
overlapping7 patient collectives, reported CBF to be markedly reduced
in RR-MS. A recent study9 employed yet another technique, ASL, and
found a less pronounced but still significant CBF reduction in patients
with RR-MS. We performed Monte Carlo simulations with values re-
ported in these studies and demonstrated a DCE-MRI study to have
high (>80%) statistical power to discriminate NAWM hypoperfusion
for all effect sizes but those reported in the ASL study (see Table 2).www.investigativeradiology.com 139
ealth, Inc. All rights reserved.
Ingrisch et al Investigative Radiology • Volume 52, Number 3, March 2017Taken together, these findings indicate that, in our patient group,
NAWM hypoperfusion may either be nonexistent or must be notably
less pronounced than reported in previous studies.
A recent study11 reported NAWM perfusion not only to be not
reduced in a subgroup with “highly active” MS but even to be higher
than in control patients. In this study, patients were followed up by
monthly MRI examinations, and highly active was defined as a marked
increase in the number of contrast-enhancing lesions.11 In our patient
cohort, no follow-up data were available due to our cross-sectional
study design, so that this definition of highly active MS could not be
used. A surrogate marker of disease activity, the total number of
contrast-enhancing lesions, was not associated with a difference in
NAWM perfusion. In addition, no statistically significant differences
in CBF or CBV between patient groups emerged when patients with
contrast-enhancing lesions were excluded from the analysis. Neverthe-
less, the existence of MS subgroups with increased and reduced
NAWM perfusion suggests that the role of NAWM perfusion in MS
is not yet fully understood and requires further investigation.
A potential explanation for the discrepancy between early studies
reporting a pronounced hypoperfusion and recent studies9,11 may be
found in the “winner's course.”21 This is a statistical phenomenon by
which the first studies to report a significant effect usually overestimate
the effect size, resulting from a combination of small sample sizes and
low statistical power. In the present study, we have derived estimates of
the statistical power of our study design by means of a simulation study
and demonstrated our study to have sufficient statistical power to detect
previously reported large differences in NAWM perfusion.
We observed values for CBF and CBV that are well below those
published in the literature. This underestimation is present in both pa-
tient groups, indicating a systematic effect. By using the absolute signal
enhancement as approximation of the concentration, we have utilized a
very simple, linear signal model. When large values for the concentra-
tion are reached, for example, during the first pass of contrast agent in
the vessels, the underlying linearity assumption may be violated. This
would, however, cause an underestimation of the AIF and hence an
overestimation of CBF and CBV, contrary to the observations. This
leaves water exchange effects as a possible explanation for our observa-
tion. These effects are particularly relevant when large differences in re-
laxation rates occur, for example, during the first pass of contrast agent,
where the intravascular contrast agent concentration and hence the re-
laxation rate is large. When not accounted for in the signal analysis,
this leads to an underestimation of the contrast agent concentration,
which, in turn, causes an underestimation of CBF and CBV.22,23 The
exact amount of this underestimation depends on several parameters
of the pulse sequence that is used for acquisition,24,25 but also on the
transendothelial water exchange rate. Utilizing a more complex signal
model23 would have accounted for both nonlinearities and water ex-
change effects, but would have required maps of precontrast relaxa-
tion rate and possibly flip angle; these data were not available in this
study. In our study, we found PS to be zero in both patient groups;
hence, we assume that the transendothelial water exchange is unlikely
to be different between patient groups. Therefore, we do not expect
that effects of slow water exchange influence the comparison of
patient groups.
A major difficulty in perfusion MRI is the lack of standardiza-
tion of data acquisition and quantification, partly due to the absence
of an accepted criterion standard. Cerebral perfusionMRI has long been
dominated by DSCMRI due to the large CNR, but absolute quantifica-
tion of DSC remains challenging.26 In particular, in light of the recent
discussion about gadolinium deposition in the brain,27–29 ASL is a very
attractive technique for the assessment of cerebral perfusion because it
does not require the administration of contrast agent. Although NAWM
hypoperfusion in MS has been demonstrated recently by means of
ASL,9 the detection of white matter perfusion abnormalities by ASL
is seen critically.30 In the present work, we have chosen a DCE-MRI140 www.investigativeradiology.com
Copyright © 2017 Wolters Kluwer Happroach, which allowed us to measure CBF, CBV, and PS simulta-
neously, but this approach is limited by the low CNR that results from
the low CBV in healthy brain tissue. An increase in CNR, for example,
by using a larger voxel size, would be very helpful to detect subtle dif-
ferences in perfusion below the detection limit of our study, but an
upper limit on the voxel size is imposed by the need of measuring
an AIF. Our modeling approach followed an emerging standardiza-
tion of notation and tracer-kinetic modeling,31,32 thereby improving
interstudy comparability.
Recently, subtle BBB leakage in NAWM has been reported in
patients with MS.33 While our approach in principle allows for a mea-
surement of PS as a surrogate marker of BBB leakage, our study was
not optimized for this purpose. Because the focus of our study was to
detect differences in CBF, we have not estimated the statistical power
for the detection of increased PS. For a reliable measurement of sub-
tle BBB leakage, a longer total acquisition time from 1534 to 2535mi-
nutes, combined with corrections for scanner drift and possibly image
registration to account for patient movement, would have been benefi-
cial35; the total acquisition time in our study may not have been suffi-
cient to resolve small values of PS.
Our study is not without limitations. The age distributions of
the 2 patient groups are not fully matched. However, the statistical
analysis of our data did not reveal a significant influence of age on
cerebral perfusion in either group of our patient cohort. Moreover,
the statistical model would have adjusted for potential effects of
age. In addition, we were not able to classify our patients into
“high-inflammatory” and “low-inflammatory”11 due to the cross-
sectional design of our study, which limited the respective subgroup
analyses. Nevertheless, the exclusion of patients with CE-lesions did
not alter the statistical results.
In conclusion, we were not able to confirm previous observa-
tions of NAWM hypoperfusion in MS in our patient groups, despite
high statistical power for all but the most subtle previously reported dif-
ferences. A possible explanation for this negative result is that—at least
in our patient cohort—potential NAWM hypoperfusion is much less
pronounced than reported in most previous studies.REFERENCES
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